How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?
Do you think it works better if incorporated as early as possible in the patient's course, or is it better to "save it" for future recurrences after using all other available regimens?
Community PollStarted
What is your first-line treatment choice for platinum-resistant ovarian cancer?
126 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Gynecologic Oncology · The Ohio State University College of Medicine
Answered on
This question is going to be increasingly important in the current landscape of ovarian cancer management.
I have prioritized early ordering of biomarker testing so that I have the test profiles available at recurrence, particularly in the platinum-resistant standpoint.
I find that toxicity, patient ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Gynecologic Oncology · Texas Oncology-The Woodlands
Answered on
Related to Q1, this has been on my radar for a couple of years as I was the PI for SORAYA, so I had access to the agent before FDA accelerated approval – now with regular approval. Since the MIRASOL trial demonstrated benefit over standard single agent chemotherapy, it’s preferred if eligible. I am ...
Join for free or sign in to see the full answer